Citation Impact
Citing Papers
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
2014
Long-term treatment of epilepsy with everolimus in tuberous sclerosis
2016
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist
2004 StandoutNobel
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
2010
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
2010
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
2010
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
2002
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective
2010
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Hallmarks of Cancer: The Next Generation
2011 Standout
Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer
2006
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
2008
PET/MRI Dual-Modality Tumor Imaging Using Arginine-Glycine-Aspartic (RGD)–Conjugated Radiolabeled Iron Oxide Nanoparticles
2008
EGFR Antagonists in Cancer Treatment
2008 Standout
Environmental chemistry of phosphonates
2003
IDH1andIDH2Mutations in Gliomas
2009 Standout
The Tuberous Sclerosis Complex
2006 Standout
Positive and Negative Regulation of TSC2 Activity and Its Effects on Downstream Effectors of the mTOR Pathway
2005
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
2004
Genotype/phenotype correlation in 325 individuals referred for a diagnosis of tuberous sclerosis complex in the United States
2007
Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease
2005
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma†
2006
Drug development and clinical trials—the path to an approved cancer drug
2012
Cancer Metastasis: Building a Framework
2006 Standout
IDH mutations in glioma and acute myeloid leukemia
2010
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
HIF2α cooperates with RAS to promote lung tumorigenesis in mice
2009 StandoutNobel
Rapamycin: One Drug, Many Effects
2014 Standout
Topical Use of Mammalian Target of Rapamycin (mTOR) Inhibitors in Tuberous Sclerosis Complex—A Comprehensive Review of the Literature
2016
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Renal manifestations of tuberous sclerosis complex: Incidence, prognosis, and predictive factors
2006
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Tuberous sclerosis complex: Advances in diagnosis, genetics, and management
2007
Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Imaging angiogenesis of genitourinary tumors
2010
Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
2012
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
2015 Standout
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
The 1p-Encoded Protein Stathmin and Resistance of Malignant Gliomas to Nitrosoureas
2007
Molecular and clinical analyses of 84 patients with tuberous sclerosis complex
2006
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
2014
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
Mutational Analysis in a Cohort of 224 Tuberous Sclerosis Patients Indicates Increased Severity of TSC2, Compared with TSC1, Disease in Multiple Organs
2001
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO* Task Force
2010
Biomedical applications of bisphosphonates
2013
Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease
2010 Standout
Autophagy in the Pathogenesis of Disease
2008 Standout
Raise standards for preclinical cancer research
2012 StandoutNature
Lymphangioleiomyomatosis — a wolf in sheep’s clothing
2012
Hypoxia and TGF-β Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment
2009
Anaplastic Oligodendroglioma and Oligoastrocytoma
2007
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
2009
Endothelin—Biology and disease
2010
Tuberous sclerosis
2008 Standout
Malignant Gliomas in Adults
2008 Standout
mTOR treatment in lymphangioleiomyomatosis: the role of everolimus
2016
The Neurology of mTOR
2014
IDH1 mutation of gliomas with long-term survival analysis
2012
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations
2007
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Cancer immunotherapy comes of age
2011 StandoutNature
Primary brain tumours in adults
2003
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
2010 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
The Neurobiology of the Tuberous Sclerosis Complex
2006
Primary brain tumours in adults
2012 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
2006
AKT/PKB Signaling: Navigating the Network
2017 Standout
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Selective internal radiation therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma
2006
Antiangiogenic therapies for high-grade glioma
2009
The endothelin axis: emerging role in cancer
2003
The PI3K Pathway in Human Disease
2017 Standout
Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways
2005
Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway
2016
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Tumor Angiogenesis
2008 Standout
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Osteoblasts in prostate cancer metastasis to bone
2005
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
2006
Tuberous sclerosis complex: From molecular biology to novel therapeutic approaches
2016
Tuberous sclerosis
2006
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy.
2009
Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards
2005
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation
2015
Copper-Catalyzed Synthesis of Mixed Alkyl Aryl Phosphonates
2014 StandoutNobel
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
2007
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Lutetium-177 Therapeutic Radiopharmaceuticals: Linking Chemistry, Radiochemistry, and Practical Applications
2015
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
2016 StandoutNobel
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
2014
Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2
2005
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
2001
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex
2016
Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
2008 Standout
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
2003
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
2006
Mammalian Target of Rapamycin Complex 1 Suppresses Lipolysis, Stimulates Lipogenesis, and Promotes Fat Storage
2010
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
2004
Works of Bernard A. Zonnenberg being referenced
Cognitive impairment in tuberous sclerosis complex is a multifactorial condition
2007
Lanthanide-Loaded Liposomes for Multimodality Imaging and Therapy
2006
High Rate of Mosaicism in Tuberous Sclerosis Complex
1999
Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial
2015
Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex
2011
Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial
2008
Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype – phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex
2005
Fatty Foci in the Myocardium in Patients with Tuberous Sclerosis Complex: Common Finding at CT
2009
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
2001
Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature
2009
Targeting of liver tumour in rats by selective delivery of holmium-166 loaded microspheres: a biodistribution study
2001
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
2013
Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
2007
Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques
1999
Suppression of Prostate Cancer Induced Bone Remodeling by The Endothelin Receptor a Antagonist Atrasentan
2003
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
2003
3LB ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer (HRPC) and bone metastases
2007
Everolimus therapy for angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: Results from EXIST-2.
2012
Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial
2003
Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration‐resistant prostate cancer and bone metastases who were pain‐free or mildly symptomatic for pain: a double‐blind, placebo‐controlled, randomized Phase II trial
2010
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
1998
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
2002
Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
1992
IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide
2009
Microsphere radioembolization of liver malignancies: current developments.
2009
Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
2003